| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tatiana M Korotkova, Olga A Sergeeva, Krister S Eriksson, Helmut L Haas, Ritchie E Brow. Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 1. 2003-01-27. PMID:12514194. |
in narcolepsy, in which the orexin system is disrupted, dysfunction of the orexin modulation of vta neurons may be important in triggering attacks of cataplexy. |
2003-01-27 |
2023-08-12 |
Not clear |
| S Gulyani, M-F Wu, R Nienhuis, J John, J M Siege. Cataplexy-related neurons in the amygdala of the narcoleptic dog. Neuroscience. vol 112. issue 2. 2002-08-29. PMID:12044453. |
cataplexy, a symptom of narcolepsy, is a loss of muscle tone usually triggered by sudden, strong emotions. |
2002-08-29 |
2023-08-12 |
dog |
| M Okura, N Fujiki, B Ripley, S Takahashi, N Amitai, E Mignot, S Nishin. Narcoleptic canines display periodic leg movements during sleep. Psychiatry and clinical neurosciences. vol 55. issue 3. 2001-09-27. PMID:11422858. |
the observation that d2/d3 agonists aggravate cataplexy in narcoleptic dogs suggests that altered dopaminergic regulation in canine narcolepsy may play a critical role in both cataplexy and plms. |
2001-09-27 |
2023-08-12 |
Not clear |
| M Okura, J Riehl, E Mignot, S Nishin. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 23. issue 5. 2000-11-21. PMID:11027918. |
sulpiride, a d2/d3 blocker, reduces cataplexy but not rem sleep in canine narcolepsy. |
2000-11-21 |
2023-08-12 |
human |
| M Okura, J Riehl, E Mignot, S Nishin. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 23. issue 5. 2000-11-21. PMID:11027918. |
we therefore assessed the effects of sulpiride, a commonly used d2/d3 antagonist, on cataplexy and sleep in narcoleptic canines to explore the possible clinical application of d2/d3 antagonists for the treatment of human narcolepsy. |
2000-11-21 |
2023-08-12 |
human |
| T Kanbayashi, K Honda, T Kodama, E Mignot, S Nishin. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Neuroscience. vol 99. issue 4. 2000-11-07. PMID:10974428. |
in order to further delineate the respective roles of the dopaminergic and noradrenergic systems in the pharmacological control of symptoms of narcolepsy, we compared the potency of amphetamine isomers (d- and l-amphetamines) and a derivative (l-methamphetamine) on wakefulness and cataplexy. |
2000-11-07 |
2023-08-12 |
Not clear |
| P F Bladi. Narcolepsy -- cataplexy and psychoanalytic theory of sleep and dreams. Journal of the history of the neurosciences. vol 9. issue 2. 2000-10-23. PMID:11608942. |
narcolepsy -- cataplexy and psychoanalytic theory of sleep and dreams. |
2000-10-23 |
2023-08-12 |
Not clear |
| S Nishino, K Honda, J Riehl, M Okura, E Migno. Neuronal activity in the cholinoceptive basal forebrain of freely moving narcoleptic dobermans. Neuroreport. vol 9. issue 16. 1999-02-26. PMID:9858375. |
cholinergic stimulation in the basal forebrain (bf) triggers cataplexy in canine narcolepsy. |
1999-02-26 |
2023-08-12 |
Not clear |
| E Mignot, R Hayduk, J Black, F C Grumet, C Guilleminaul. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. vol 20. issue 11. 1998-04-23. PMID:9456467. |
we hla typed 509 patients enrolled in a clinical trial for the drug modafinil and analyzed the results in relation to cataplexy, a symptom of narcolepsy characterized by muscle weakness triggered by emotions. |
1998-04-23 |
2023-08-12 |
human |
| K Honda, J Riehl, S Inoué, E Mignot, S Nishin. Central administration of vitamin B12 aggravates cataplexy in canine narcolepsy. Neuroreport. vol 8. issue 18. 1998-03-19. PMID:9462456. |
experimental evidence in canine narcolepsy suggests that central cholinergic systems are critically involved in the regulation of cataplexy, an abnormal manifestation of rem sleep atonia. |
1998-03-19 |
2023-08-12 |
Not clear |
| R Sandy. Resolution of partial cataplexy in multiple sclerosis by treatment with weak electromagnetic fields. The International journal of neuroscience. vol 84. issue 1-4. 1996-09-09. PMID:8707478. |
cataplexy, an ancillary symptom of narcolepsy, involves the sudden loss of muscle tone without altered consciousness usually brought on by sudden excitement or emotional influence and extreme exertions (guilleminault et al., 1974; parks et al., 1974; guilleminault, 1976; aldrich, 1992; 1993; scrima, 1981; baker, 1985). |
1996-09-09 |
2023-08-12 |
Not clear |
| D G Vossler, A R Wyler, R J Wilkus, G Gardner-Walker, B W Vlce. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology. vol 46. issue 5. 1996-06-21. PMID:8628463. |
data from the canine narcolepsy syndrome model implicate abnormal catecholaminergic and cholinergic activities in the pathogenesis of cataplexy. |
1996-06-21 |
2023-08-12 |
human |
| D Nitz, A Andersen, H Fahringer, R Nienhuis, E Mignot, J Siege. Altered distribution of cholinergic cells in the narcoleptic dog. Neuroreport. vol 6. issue 11. 1995-11-28. PMID:7579139. |
narcolepsy is characterized by excessive sleepiness and episodes of cataplexy brought on by emotional excitation. |
1995-11-28 |
2023-08-12 |
dog |
| D Nitz, A Andersen, H Fahringer, R Nienhuis, E Mignot, J Siege. Altered distribution of cholinergic cells in the narcoleptic dog. Neuroreport. vol 6. issue 11. 1995-11-28. PMID:7579139. |
this abnormality can explain alterations in cholinergic receptor number, acetylcholine release, and the occurrence of cataplexy and sleep paralysis that characterize narcolepsy. |
1995-11-28 |
2023-08-12 |
dog |
| H B Gernaat, P M Haffmans, H Knegtering, T K Birkenhäge. Tranylcypromine in narcolepsy. Pharmacopsychiatry. vol 28. issue 3. 1995-11-06. PMID:7568373. |
we report on a patient with severe narcolepsy in whom administration of tranylcypromine led to freedom from hallucinations, nightmares, sleep paralysis, and rapid eye movements (rem), with considerable amelioration of cataplexy and increased daytime alertness. |
1995-11-06 |
2023-08-12 |
Not clear |
| S Nishino, M Tafti, M S Reid, J Shelton, J M Siegel, W C Dement, E Migno. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 15. issue 7 Pt 1. 1995-08-28. PMID:7623112. |
the pontine cholinergic system is, therefore, likely to play a role in triggering cataplexy and other rem-related abnormalities seen in narcolepsy. |
1995-08-28 |
2023-08-12 |
Not clear |
| S Nishino, J Shelton, A Renaud, W C Dement, E Migno. Effect of 5-HT1A receptor agonists and antagonists on canine cataplexy. The Journal of pharmacology and experimental therapeutics. vol 272. issue 3. 1995-04-14. PMID:7891329. |
pharmacological studies using a canine model of narcolepsy have demonstrated that adrenergic rather than serotonergic or dopaminergic uptake inhibition is the primary mode of action of antidepressants on cataplexy, a pathological manifestation of rapid eye movement (rem) sleep atonia that occurs in narcolepsy. |
1995-04-14 |
2023-08-12 |
human |
| M S Reid, M Tafti, S Nishino, J M Siegel, W C Dement, E Migno. Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Sleep. vol 17. issue 5. 1995-01-12. PMID:7991953. |
cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by m2 muscarinic receptors. |
1995-01-12 |
2023-08-12 |
Not clear |
| M S Reid, M Tafti, J N Geary, S Nishino, J M Siegel, W C Dement, E Migno. Cholinergic mechanisms in canine narcolepsy--I. Modulation of cataplexy via local drug administration into the pontine reticular formation. Neuroscience. vol 59. issue 3. 1994-07-21. PMID:8008205. |
cholinergic mechanisms in canine narcolepsy--i. modulation of cataplexy via local drug administration into the pontine reticular formation. |
1994-07-21 |
2023-08-12 |
Not clear |
| S Nishino, J Arrigoni, J Shelton, W C Dement, E Migno. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. vol 16. issue 8. 1994-05-24. PMID:8165384. |
our series of pharmacological studies on canine narcolepsy has suggested that the adrenergic systems are more critically involved in the regulation of cataplexy than the serotonergic and dopaminergic systems. |
1994-05-24 |
2023-08-12 |
human |